Association of pretreatment with angiotensin-converting enzyme inhibitors with improvement in ablation outcome in atrial fibrillation patients with low left ventricular ejection fraction

Heart Rhythm

Volumn 12, Issue 9, 2015, Pages 1963-1971

  Mohanty, Sanghamitra ^a   Mohanty, Prasant ^a   Trivedi, Chintan ^a   Gianni, Carola ^a,b   Bai, Rong ^a,c   Burkhardt, John David ^a   Gallinghouse, Joseph G ^a   Horton, Rodney ^a,d   Sanchez, Javier E ^a   Hranitzky, Patrick M ^a   Al Ahmad, Amin ^a   Bailey, Shane ^a   Di Biase, Luigi ^a,d,e,f   Natale, Andrea ^{a,d,g,h,i,j,k,l}  

^a TEXAS CARDIAC ARRHYTHMIA INSTITUTE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d The University of Texas at Austin   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

^f UNIVERSITY OF FOGGIA   (Italy)

^g CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^h SCRIPPS CLINIC   (United States)

ⁱ UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^j STANFORD UNIVERSITY   (United States)

^k CASE WESTERN RESERVE UNIVERSITY   (United States)

^l ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Ablation outcome; AF related hospitalization; Angiotensin converting enzyme inhibitors; Low left ventricular ejection fraction; Nonparoxysmal atrial fibrillation

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CATHETER ABLATION; CONTROLLED STUDY; COST CONTROL; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOFREQUENCY; REPEAT PROCEDURE; RISK REDUCTION; SINUS RHYTHM; VERY ELDERLY; ADOLESCENT; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; INCIDENCE; MIDDLE AGED; PATHOPHYSIOLOGY; PREOPERATIVE CARE; PROCEDURES; SURVIVAL RATE; TIME FACTOR; TREATMENT OUTCOME; TRENDS; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; CATHETER ABLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROSPECTIVE STUDIES; STROKE VOLUME; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84939788861     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2015.06.007     Document Type: Article

References (42)

1. I. Savelieva, N. Kakouros, A. Kourliouros, and A.J. Camm Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines: part I: primary prevention Europace 13 2011 308 328
2. Cedars-Sinai Medical Center. WHO study: Atrial fibrillation is growing global health concern. ScienceDaily Web site. December 17, 2013. www.sciencedaily.com/releases/2013/12/131217170852.htm. Accessed November 1, 2014.
3. N.J. Patel, A. Deshmukh, S. Pant, and et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning Circulation 129 2014 2371 2379
4. E. Vermes, J.C. Tardif, M.G. Bourassa, N. Racine, S. Levesque, M. White, P.G. Guerra, and A. Ducharme Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials Circulation 107 2003 2926 2931
5. I. Savelieva, N. Kakouros, A. Kourliouros, and A.J. Camm Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines, part II: secondary prevention Europace 13 2011 610 625
6. J.S. Healey, C.A. Morillo, and S.J. Connolly Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling Curr Opin Cardiol 20 2005 31 37
7. Y. Zhang, P. Zhang, Y. Mu, M. Gao, J.R. Wang, Y. Wang, L.Q. Su, and Y.L. Hou The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials Clin Pharmacol Ther 88 2010 521 531
8. S. Lévy Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation: indications and contraindications Nat Clin Pract Cardiovasc Med 3 2006 220 225
9. N. Hamdani, and W.J. Paulus Treatment of heart failure with normal ejection fraction Curr Treat Options Cardiovasc Med 13 2011 26 34
10. W. Anné, R. Willems, N. Van der Merwe, F. Van de Werf, H. Ector, and H. Heidbüchel Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics Heart 90 2004 1025 1030
11. A.N. Amin, M. Jhaveri, and J. Lin Hospital readmissions in US atrial fibrillation patients: occurrence and costs Am J Ther 20 2013 143 150
12. S.D. Solomon, N. Anavekar, H. Skali, J.J. McMurray, K. Swedberg, S. Yusuf, C.B. Granger, E.L. Michelson, D. Wang, S. Pocock, and M.A. Pfeffer for the Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients Circulation 112 2005 3738 3744
13. L. Di Biase, J.D. Burkhardt, P. Mohanty, and et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation Circulation 122 2010 109 118
14. L. Di Biase, J.D. Burkhardt, P. Santangeli, and et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial Circulation 129 2014 2638 2644
15. K.T. Murray, J.N. Rottman, P.G. Arbogast, and et al. AFFIRM Investigators. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM Heart Rhythm 1 2004 669 675
16. C.T. Tsai, L.P. Lai, J.L. Lin, F.T. Chiang, J.J. Hwang, M.D. Ritchie, J.H. Moore, K.L. Hsu, C.D. Tseng, C.S. Liau, and Y.Z. Tseng Renin-angiotensin system gene polymorphisms and atrial fibrillation Circulation 109 2004 1640 1646
17. F. Belluzzi, L. Sernesi, P. Preti, F. Salinaro, M.L. Fonte, and S. Perlini Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients J Am Coll Cardiol 53 2009 24 29
18. M. Han, Y. Zhang, S. Sun, Z. Wang, J. Wang, X. Xie, M. Gao, X. Yin, and Y. Hou Renin-angiotensin system inhibitors prevent the recurrence of atrial fibrillation: a meta-analysis of randomized controlled trials J Cardiovasc Pharmacol 62 2013 405 415
19. M.O. Al Chekakie, J.G. Akar, F. Wang, H. Al Muradi, J. Wu, P. Santucci, N. Varma, and D.J. Wilber The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation J Cardiovasc Electrophysiol 18 2007 942 946
20. B. Zheng, J. Kang, Y. Tian, and et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have no beneficial effect on ablation outcome in chronic persistent atrial fibrillation Acta Cardiol 64 2009 335 340
21. B. Richter, M. Derntl, M. Marx, P. Lercher, and H.D. Gössinger Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation Am Heart J 153 2007 113 119
22. M.H. Tayebjee, A. Creta, S. Moder, R.J. Hunter, M.J. Earley, M.B. Dhinoja, and R.J. Schilling Impact of angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers on long-term outcome of catheter ablation for atrial fibrillation Europace 12 2010 1537 1542
23. D. Patel, P. Mohanty, L. Di Biase, and et al. The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females Europace 12 2010 322 330
24. W.S. Lin, C.T. Tai, M.H. Hsieh, C.F. Tsai, Y.K. Lin, H.M. Tsao, J.L. Huang, W.C. Yu, S.P. Yang, Y.A. Ding, M.S. Chang, and S.A. Chen Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy Circulation 107 2003 3176 3183
25. L. Di Biase, P. Santangeli, and A. Natale How to ablate long-standing persistent atrial fibrillation? Curr Opin Cardiol 28 2013 26 35
26. D. Lin, D.S. Frankel, E.S. Zado, and et al. Pulmonary vein antral isolation and nonpulmonary vein trigger ablation without additional substrate modification for treating longstanding persistent atrial fibrillation J Cardiovasc Electrophysiol 23 2012 806 813
27. J.H. Park, Y.S. Oh, J.H. Kim, and et al. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on patients following ablation of atrial fibrillation Korean Circ J 39 2009 185 189
28. H.U. Klemm, T. Heitzer, U. Ruprecht, T. Meinertz, and R. Ventura Impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the long-term outcome after pulmonary vein isolation for paroxysmal atrial fibrillation Cardiology 117 2010 14 20
29. K. Ishikawa, T. Yamada, Y. Yoshida, M. Takigawa, Y. Aoyama, N. Inoue, Y. Tatematsu, M. Nanasato, K. Kato, N. Tsuboi, and H. Hirayama Renin-angiotensin system blocker use may be associated with suppression of atrial fibrillation recurrence after pulmonary vein isolation Pacing Clin Electrophysiol 34 2011 296 303
30. O. Salehian, J. Healey, B. Stambler, and et al. HOPE Investigators. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study Am Heart J 154 2007 448 453
31. J.G. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, and J. Taylor PEP-CHF Investigators. The Perindopril in Elderly People With Chronic Heart Failure (PEP-CHF) study Eur Heart J 27 2006 2338 2345
32. A. Ducharme, K. Swedberg, M.A. Pfeffer, and et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program Am Heart J 152 2006 86 92
33. K.M. Makkar, C.A. Sanoski, and S.A. Spinler Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias Pharmacotherapy 29 2009 31 48
34. A. Goette, N. Schön, P. Kirchhof, G. Breithardt, T. Fetsch, K.G. Häusler, H.U. Klein, G. Steinbeck, K. Wegscheider, and T. Meinertz Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial Circ Arrhythm Electrophysiol 5 2012 43 51
35. K.C. Ueng, T.P. Tsai, W.C. Yu, C.F. Tsai, M.C. Lin, K.C. Chan, C.Y. Chen, D.J. Wu, C.S. Lin, and S.A. Chen Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: results of a prospective and controlled study Eur Heart J 24 2003 2090 2098
36. A.H. Madrid, M.G. Bueno, J.M. Rebollo, I. Marín, G. Peña, E. Bernal, A. Rodriguez, L. Cano, J.M. Cano, P. Cabeza, and C. Moro Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study Circulation 106 2002 331 336
37. J.R. Ehrlich, S.H. Hohnloser, and S. Nattel Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence Eur Heart J 27 2006 512 518
38. Z. Kucukdurmaz, R. Kato, A. Erdem, E. Golcuk, T. Tobiume, T. Nagase, Y. Ikeda, Y. Nakajima, M. Matsumura, N. Komiyama, S. Nishimura, and K. Matsumoto Catheter ablation for atrial fibrillation results in greater improvement in cardiac function in patients with low versus normal left ventricular ejection fraction J Interv Card Electrophysiol 37 2013 179 187
39. L.F. Hsu, P. Jaïs, P. Sanders, and et al. Catheter ablation for atrial fibrillation in congestive heart failure N Engl J Med 351 2004 2373 2383
40. M. Wagner, D. Rindress, B. Desjardins, M.C. Meilleur, A. Ducharme, and J.C. Tardif Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril Am Heart J 150 2005 985
41. J.R. Cook, H.A. Glick, W. Gerth, B. Kinosian, and J.B. Kostis The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction Am J Hypertens 11 1998 1433 1441
42. H. Glick, J. Cook, B. Pitt, M.G. Bourassa, H. Pouleur, and W. Gerth Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial J Card Fail 1 1995 371 380